Global venture capital (VC) funding for the Digital Health sector came to $44 billion since 2010. Of the $44 billion VC funding raised, practice-focused companies raised $18 billion while remaining $26 billion was raised by consumer-centric technologies which include, mHealth Apps, Wearable Sensors, Telemedicine, Mobile Wireless Devices.
Among the practice-focused categories: Data Analytics companies led the funding activity with $6.2 billion, followed by Clinical Decision Support with $3 billion.
Practice focused companies that originated from the United States have attracted the most VC funding since 2010, with over $14 billion, followed by China with over $900 million. The rest of the funding was spread across the world in 30 countries, including Canada, the U.K., Israel, Germany, and Switzerland.
Over 1,800 investors have participated in Digital Health practice-focused funding deals since 2010.
Khosla Ventures, Norwest Venture Partners, GV (formerly Google Ventures), Warburg Pincus, and Sequoia Capital led the digital health practice-focused investment activity since 2010.
Top VC funded practice-focused companies Since 2010:
In a large funding deal, WuXi Nextcode – a genomics data platform that generates, organizes, mines, shares, and applies genomic data for population genomics projects, clinical diagnostics, and applications, as well as scientific wellness – completed a $200 million Series C financing round. In a similar deal, last year, the genomic data analysis platform Tempus raised $200 million in Series F financing at a valuation of $3.1 billion.
SomaLogic, a precision digital health company that provides health-management insights based on comprehensive measurements of personal protein profiles and enhances clinical decision making, raised $200 million in funding. PointClickCare, the developer of a cloud-based electronic health records platform designed for the long-term post-acute care and senior living markets, closed an $85 million financing.
Exo Imaging, a developer of AI-enabled medical imaging and therapeutic applications, raised $35 million in a Series B financing round led by Intel Capital.